Urogenital atrophy, also known as vaginal atrophy or atrophic vaginitis, is a condition characterized by the thinning, drying, and inflammation of the vaginal walls, often accompanied by changes in the urinary tract. It commonly occurs due to a decrease in estrogen levels, particularly during menopause.
Several factors can contribute to urogenital atrophy, including:
Reduced estrogen production during menopause leads to significant changes in the vaginal tissues, resulting in thinning, dryness, and decreased elasticity. These hormonal shifts can also affect the urinary tract, leading to symptoms of urogenital atrophy.
Estrogen levels can decrease due to various factors beyond menopause, such as childbirth, breastfeeding, or certain medications (like those used in the treatment of breast cancer). These changes can impact vaginal health and moisture levels, contributing to urogenital atrophy.
Cancer treatments, particularly radiation therapy or surgical procedures like hysterectomy, can disrupt estrogen levels in the body. Reduced estrogen can lead to changes in the vaginal tissues, resulting in symptoms of urogenital atrophy.
While not directly a cause, smoking can exacerbate symptoms of urogenital atrophy. Smoking has been linked to decreased estrogen levels, which can further contribute to vaginal dryness and irritation.
Certain health conditions like Sjögren’s syndrome or autoimmune diseases can affect moisture-producing glands in the body, including those in the vaginal area, leading to symptoms of urogenital atrophy.
Symptoms of urogenital atrophy encompass various manifestations, including:
Insufficient natural lubrication in the vaginal area leads to discomfort or pain during sexual intercourse. This dryness results from reduced moisture production and elasticity in the vaginal tissues.
Irritation or a burning sensation in the vaginal area, often accompanied by redness or soreness. This discomfort arises due to the thinning and fragility of the vaginal tissues.
Individuals may experience increased urinary frequency, urgency, or recurrent urinary tract infections due to changes in the urethral and bladder tissues. These changes can lead to discomfort or urinary symptoms.
Some individuals may notice spotting or light bleeding after intercourse due to the fragility of the vaginal tissues, which are more prone to tearing or irritation.
Discomfort or pain during sexual activity (dyspareunia) is common due to the lack of vaginal lubrication and thinning of the vaginal walls.
In some cases, urogenital atrophy can contribute to urinary incontinence or leakage, particularly when coughing, sneezing, or engaging in physical activities.
Risk factors for developing urogenital atrophy might include:
Decreased estrogen levels during and after menopause.
Hormonal changes during breastfeeding might contribute.
Certain medications or treatments affecting estrogen levels.
Preventive measures might include:
Maintaining sexual activity to promote blood flow and vaginal elasticity.
Discussing HRT options with a healthcare provider.
Using products to alleviate dryness and discomfort.
Diagnosis involves various methods:
Discussing symptoms and conducting a physical examination.
Evaluating the vaginal and urinary tissues for signs of atrophy.
Assessing vaginal acidity levels for changes.
Treatment options for urogenital atrophy include:
Using creams, rings, or tablets containing estrogen applied directly to the vagina.
Over-the-counter products to relieve dryness and discomfort.
Oral or transdermal estrogen for overall relief of menopausal symptoms.
Estrogen replacement therapy involves the use of estrogen-containing products, such as creams, tablets, or rings, to supplement declining estrogen levels in postmenopausal women. This treatment aims to alleviate symptoms of urogenital atrophy by restoring vaginal lubrication and improving tissue health.
Laser therapy combined with Platelet-Rich Plasma (PRP) involves using laser energy to stimulate vaginal tissue followed by the application of PRP, derived from the patient’s blood. This treatment aims to rejuvenate vaginal tissues to regenerate collagen & elastin, increase blood flow, and improve symptoms associated with urogenital atrophy.
Hyaluronic acid, either in gel form or as vaginal suppositories, is used to moisturize and hydrate vaginal tissues affected by urogenital atrophy. This treatment aims to restore vaginal moisture, improve elasticity, and alleviate discomfort associated with dryness.
Address: Room 1005, Medical Plaza, 100 Amorsolo Street, Legazpi Village, Makat City
Operating Hours:
Mon, wed, & Fri: 9am to 5pm
Tues, Thurs & Sat: 2:45 pm to 2 pm
Phone: Peanut -09228253266
Email: slgcrm629@yahoo.com
Copyright © 2024 Dr. Jenny Jose
All Rights Reserved